John Jesitus is a medical writer based in Westminster, CO.
Therapeutic, management considerations with biologics
July 24th 2020Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Biologic guidelines for psoriasis let providers choose
April 24th 2020When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.
Molecular study highlights drug differences in atopic dermatitis
April 20th 2020A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.
Psoriasis guidelines emphasize patient education, comorbidities
April 15th 2020Current joint psoriasis guidelines from the American Academy of Dermatology and the National Psoriasis Foundation emphasize the need to help patients understand the relationship between psoriasis and comorbid conditions and the importance of seeking appropriate interventions as needed.
Eczematous eruptions in psoriasis patients using IL-17 inhibitors
February 21st 2020A recent chart review found that eczematous eruptions occurred in 5.8% of patients using interleukin (IL)-17 inhibitors for psoriasis. Its authors believe that additional research could help identify which patients may be most at risk.